Clinical Trial Update: Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of cabozantinib with ipilimumab/nivolumab and transarterial chemoembolization (TACE) for hepatocellular carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: University of California, Irvine | Conditions: Hepatocellular Carcinoma, HCC | Phase 2 | Status: RECRUITING